Unstable angina non ST elevation myocardial infarction recommendations for PCI: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 7: Line 7:
{{Editor Join}}
{{Editor Join}}


==Overview of Recommendations for PCI in UA / NSTEMI==
==Overview of Recommendations for Percutaneous coronary intervention (PCI) in Unstable angina/NSTEMI==
Coronary angiography is useful for defining the coronary artery anatomy in patients with UA/NSTEMI and for identifying subsets of high-risk patients who can benefit from early revascularization. The benefits of early invasive strategy have been discussed in previous section. Coronary revascularization with either PCI or CABG helps improve prognosis, relieve symptoms, prevent ischemic
*[[Coronary angiography]] is useful for defining the coronary artery anatomy in patients with [[UA]]/[[NSTEMI]] and for identifying subsets of high-risk patients who can benefit from early [[revascularization]]. The benefits of early invasive strategy have been discussed in previous section (see [[Unstable angina / non ST elevation myocardial infarction initial conservative versus initial invasive strategies | Initial Conservative Versus Initial Invasive Strategies]]) .  
complications, and improve functional capacity. In recent years, increased utilization of PCI has been noticed mainly secondary to technical advancements and as a result of this, less comlications associated with the procedure. PCI term refers to the whole group of percutaneous techniques, including standard balloon angioplasty (PTCA), intracoronary stenting, and atheroablative technologies
*Coronary [[revascularization]] with either [[PCI]] or [[CABG]] helps improve prognosis, relieve symptoms, prevent [[ischemic]] complications, and improve functional capacity. In recent years, increased utilization of [[PCI]] has been noticed mainly secondary to technical advancements and as a result of this, less complications associated with the procedure.  
(like atherectomy, thrombectomy, or laser angioplasty). Today, majority of PCIs involve balloon dilation and coronary stenting. wo main classes of stents available currently include bare metal stent and drug eleuting stents. Drug eluting stents have been demonstrated to markedly reduce the risk of restenosis compared with bare-metal stents. With the increasing use of GP IIb/IIIa inhibitors, clopidogrel, and/or other antithrombotic drugs in UA/NSTEMI patients, complications related to PCI have decreased dramatically and both acute and long-term outcomes following PCI have improved with success rates as high as 95%.
*[[PCI]] term refers to the whole group of percutaneous techniques, including standard [[balloon angioplasty]] ([[PTCA]]), [[intracoronary stenting]], and atheroablative technologies(like [[atherectomy]], [[thrombectomy]], or laser [[angioplasty]]). Today, majority of PCIs involve [[balloon dilation]] and [[coronary stenting]].  
*Two main classes of [[stents]] available currently include [[bare metal stent]] and [[drug eluting stents]]. Drug eluting stents have been demonstrated to markedly reduce the risk of [[restenosis]] compared with bare-metal stents.  
*With the increasing use of [[GP IIb/IIIa inhibitors]], [[clopidogrel]], and/or other [[antithrombotic]] drugs in [[UA]]/[[NSTEMI]] patients, complications related to [[PCI]] have decreased dramatically and both acute and long-term outcomes following PCI have improved with success rates as high as 95%.


==Platelet Inhibitors and PCI==
===ACC / AHA Guidelines-Recommendations for PCI in patients with UA/NSTEMI (DO NOT EDIT) <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=[[Journal of the American College of Cardiology]] |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi=10.1016/j.jacc.2007.02.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00511-6 |accessdate=2011-04-13}}</ref>===
[[Aspirin]] is one of the oldest platelet inhibitors and has been repeatedly shown to improve outcomes in [[CAD]] patients. Thienopyridines(like [[clopidogrel]], [[prasugrel]], [[ticagrelor]]) are becoming increasingly important in PCI patients due to their benefit in reducing stent thrombosis. Along with aspirin, thienopyridines form the dual antiplatelet therapy for PCI patients. An important advance in the treatment of patients with [[UA]]/[[NSTEMI]] who are undergoing PCI was the introduction of platelet GP IIb/IIIa receptor inhibitors(like [[abciximab]], [[tirofiban]], [[eptifibatide]]) in the 1990s. All three GP IIb/IIIa inhibitors have been shown to reduce the incidence of ischemic complications in patients with [[UA]]/[[NSTEMI]]. Thienopyridines i.e. either prasugrel or clopidogrel are now routinely recommended before or at the time of PCI along with aspirin(dual antiplatelet therapy). Multiple randomized trials ahve previously shown good outcomes with the use of GP IIb/IIIa inhibitors in UA/NSTEMI patients but some recent trials ave also shown that these results may be confined to high risk grups and those with troponin elevations. EARLY ACS trial<ref name="pmid19332455">{{cite journal |author=Giugliano RP, White JA, Bode C, ''et al.'' |title=Early versus delayed, provisional eptifibatide in acute coronary syndromes |journal=N. Engl. J. Med. |volume=360 |issue=21 |pages=2176–90 |year=2009 |month=May |pmid=19332455 |doi=10.1056/NEJMoa0901316 |url=}}</ref> revealed that in patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion. ISAR-REACT 2 trial<ref name="pmid16533938">{{cite journal |author=Kastrati A, Mehilli J, Neumann FJ, ''et al.'' |title=Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial |journal=JAMA |volume=295 |issue=13 |pages=1531–8 |year=2006 |month=April |pmid=16533938 |doi=10.1001/jama.295.13.joc60034 |url=}}</ref> studied Abciximab in [[NSTEMI]] patients. This was a multicenter, randomized, double-blind, placebo-controlled study enrolling 2022 patients with non-ST-segment elevation ACS undergoing PCI. Results showed that Abciximab reduces the risk of adverse events in patients with non-ST-segment elevation ACS undergoing PCI after pretreatment with 600 mg of clopidogrel. The benefits provided by abciximab appear to be confined to patients presenting with an elevated troponin level. The benefit of GP IIb/IIIa inhibition appears greater when used in high-risk patients and in those with ST segment changes. The benefit was also seen in high risk patients with or without revascularization. Abciximab is not recommended if PCI is not planned. In the ACUITY trial<ref name="pmid17299194">{{cite journal |author=Stone GW, Bertrand ME, Moses JW, ''et al.'' |title=Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial |journal=JAMA |volume=297 |issue=6 |pages=591–602 |year=2007 |month=February |pmid=17299194 |doi=10.1001/jama.297.6.591 |url=}}</ref> superiority of early GP IIb/IIIa therapy also was not found, but investigators could not exclude as much as a 29% benefit with GP IIb/IIIa therapy nor show noninferiority of delayed administration. In addition, drug exposure before angiography was much shorter (4 hours), which might substantially diminish the opportunity for differential efficacy. Despite a lack of clarity from the overall and subgroup results, an argument can be made against the routine upstream use of GP IIb/IIIa therapy in all non–ST-elevation ACS patients intended for an invasive strategy. In particular, those with a normal baseline troponin level and those over the age of 75 years, in whom there was no evidence for benefit but who showed an increased risk of bleeding, might be excluded. On the other hand, high risk patients, diabetic patients and those with troponin elevation have been shown to have positive trends which go along with the results of previous trials. Although, this puts forward a debate to the routine early use of GP IIb/IIIa inhibitors in UA/NSTEMI patients, the current guidelines favour the use of GP IIb/IIIa inhibitors in patients undergoing PCI.
 
Also refer to the section on [[PCI]].


==ACC / AHA Guidelines-Recommendations for PCI in Patients With UA/NSTEMI(DO NOT EDIT) <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, ''et al'' |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=JACC |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi:10.1016/j.jacc.2007.02.013 |url=}}</ref>==
{{cquote|   
{{cquote|   
===Class I===
===Class I===


1. An early invasive [[PCI]] strategy is indicated for patients with [[UA]] / [[NSTEMI]] who have no serious comorbidity and who have coronary lesions amenable to [[PCI]] and any of the high risk features.  
'''1.''' An early invasive [[PCI]] strategy is indicated for patients with [[UA]] / [[NSTEMI]] who have no serious comorbidity and who have coronary lesions amenable to [[PCI]] and any of the high risk features.  


2. [[Percutaneous coronary intervention]] (or [[CABG]]) is recommended for [[UA]] / [[NSTEMI]] patients with 1 or 2 vessel [[CAD]] with or without significant proximal [[left anterior descending CAD]] but with a large area of viable [[myocardium]] and high risk criteria on non invasive testing. (Level of Evidence: B)  
'''2.''' [[Percutaneous coronary intervention]] (or [[CABG]]) is recommended for [[UA]] / [[NSTEMI]] patients with 1 or 2 vessel [[CAD]] with or without significant proximal [[left anterior descending CAD]] but with a large area of viable [[myocardium]] and high risk criteria on non invasive testing. (Level of Evidence: B)  


3. Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with multi vessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)  
'''3.''' [[Percutaneous coronary intervention]] (or [[CABG]]) is recommended for [[UA]]/[[NSTEMI]] patients with multi vessel coronary disease with suitable coronary anatomy, with normal [[LV function]], and without [[diabetes mellitus]]. (Level of Evidence: A)  


4. An intravenous platelet GP IIb/IIIa inhibitor is generally recommended in UA/NSTEMI patients undergoing PCI. (Level of Evidence: A)
'''4.''' An intravenous platelet [[GP IIb/IIIa inhibitor]] is generally recommended in [[UA]]/[[NSTEMI]] patients undergoing [[PCI]]. (Level of Evidence: A)


===Class IIa===
===Class IIa===


1. [[Percutaneous coronary intervention]] is reasonable for focal saphenous vein graft (SVG) lesions or multiple stenoses in [[UA]] / [[NSTEMI]] patients who are undergoing medical therapy and who are poor candidates for reoperative surgery. (Level of Evidence: C)  
'''1.''' [[Percutaneous coronary intervention]] is reasonable for focal saphenous vein graft ([[SVG]]) lesions or multiple stenosis in [[UA]] / [[NSTEMI]] patients who are undergoing medical therapy and who are poor candidates for reoperative surgery. (Level of Evidence: C)  


2. [[Percutaneous coronary intervention]] (or [[CABG]]) is reasonable for [[UA]] / [[NSTEMI]] patients with 1 or 2 vessel [[CAD]] with or without significant proximal [[left anterior descending CAD]] but with a moderate area of viable [[myocardium]] and ischemia on noninvasive testing. (Level of Evidence: B)  
'''2.''' [[Percutaneous coronary intervention]] (or [[CABG]]) is reasonable for [[UA]] / [[NSTEMI]] patients with 1 or 2 vessel [[CAD]] with or without significant proximal [[left anterior descending CAD]] but with a moderate area of viable [[myocardium]] and [[ischemia]] on noninvasive testing. (Level of Evidence: B)  


3. [[Percutaneous coronary intervention]] (or [[CABG]]) can be beneficial compared with medical therapy for [[UA]] / [[NSTEMI]] patients with 1 vessel disease with significant proximal [[left anterior descending CAD]]. (Level of Evidence: B)  
'''3.''' [[Percutaneous coronary intervention]] (or [[CABG]]) can be beneficial compared with medical therapy for [[UA]] / [[NSTEMI]] patients with 1 vessel disease with significant proximal [[left anterior descending CAD]]. (Level of Evidence: B)  


4. Use of PCI is reasonable in patients with [[UA]] / [[NSTEMI]] with significant [[left main CAD]] (>50% diameter stenosis) who are candidates for revascularization but are not eligible for [[CABG]] or who require emergent intervention at angiography for hemodynamic instability. (Level of Evidence: B)
'''4.''' Use of [[PCI]] is reasonable in patients with [[UA]] / [[NSTEMI]] with significant [[left main CAD]] (>50% diameter [[stenosis]]) who are candidates for [[revascularization]] but are not eligible for [[CABG]] or who require emergent intervention at [[angiography]] for hemodynamic instability. (Level of Evidence: B)


===Class IIb===
===Class IIb===


1. In the absence of high-risk features associated with [[UA]] / [[NSTEMI]], [[PCI]] may be considered in patients with [[CAD|single-vessel]] or [[CAD|multi vessel CAD]] who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. (Level of Evidence: B)
'''1.''' In the absence of high-risk features associated with [[UA]] / [[NSTEMI]], [[PCI]] may be considered in patients with [[CAD|single-vessel]] or [[CAD|multi vessel CAD]] who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. (Level of Evidence: B)


2. [[Percutaneous coronary intervention]] may be considered for [[UA]] / [[NSTEMI]] patients who are undergoing medical therapy who have 2 or 3 vessel disease, significant proximal [[left anterior descending CAD]], and treated [[diabetes]] or abnormal [[LV function]], with anatomy suitable for catheter based therapy. (Level of Evidence: B)
'''2.''' [[Percutaneous coronary intervention]] may be considered for [[UA]] / [[NSTEMI]] patients who are undergoing medical therapy who have 2 or 3 vessel disease, significant proximal [[left anterior descending CAD]], and treated [[diabetes]] or abnormal [[LV function]], with anatomy suitable for catheter based therapy. (Level of Evidence: B)


===Class III===
===Class III===


1. [[Percutaneous coronary intervention]] (or [[CABG]]) is not recommended for patients with 1 or 2 vessel [[CAD]] without significant proximal [[left anterior descending CAD]] with no current symptoms or symptoms that are unlikely to be due to [[myocardial ischemia]] and who have no [[ischemia]] on noninvasive testing. (Level of Evidence: C)
'''1.''' [[Percutaneous coronary intervention]] (or [[CABG]]) is not recommended for patients with 1 or 2 vessel [[CAD]] without significant proximal [[left anterior descending CAD]] with no current symptoms or symptoms that are unlikely to be due to [[myocardial ischemia]] and who have no [[ischemia]] on noninvasive testing. (Level of Evidence: C)


2. In the absence of high risk features associated with [[UA]] / [[NSTEMI]], [[PCI]] is not recommended for patients with [[UA]] / [[NSTEMI]] who have single vessel or multi vessel [[CAD]] and no trial of medical therapy, or who have one or more of the following:
'''2.''' In the absence of high risk features associated with [[UA]] / [[NSTEMI]], [[PCI]] is not recommended for patients with [[UA]] / [[NSTEMI]] who have single vessel or multi vessel [[CAD]] and no trial of medical therapy, or who have one or more of the following:


::a. Only a small area of [[myocardium]] at risk. (Level of Evidence: C)
::a. Only a small area of [[myocardium]] at risk. (Level of Evidence: C)
::b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. (Level of Evidence: C)
::b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. (Level of Evidence: C)
::c. A high risk of procedure related [[morbidity]] or [[mortality]]. (Level of Evidence: C)
::c. A high risk of procedure related [[morbidity]] or [[mortality]]. (Level of Evidence: C)
::d. Insignificant disease (<50% coronary stenosis). (Level of Evidence: C)
::d. Insignificant disease (<50% coronary [[stenosis]]). (Level of Evidence: C)
::e. Significant [[left main CAD]] and candidacy for [[CABG]]. (Level of Evidence: B)
::e. Significant [[left main CAD]] and candidacy for [[CABG]]. (Level of Evidence: B)


3. A [[PCI]] strategy in stable patients with persistently occluded [[infarct related coronary arteries]] after [[NSTEMI]] is not indicated. (Level of Evidence: B)}}
'''3.''' A [[PCI]] strategy in stable patients with persistently occluded [[infarct related coronary arteries]] after [[NSTEMI]] is not indicated. (Level of Evidence: B)}}




==ACC/AHA Guidelines for the Timing of Angiography and Antiplatelet Therapy in UA/NSTEMI(DO NOT EDIT)<ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, ''et al'' |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=JACC |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi:10.1016/j.jacc.2007.02.013 |url=}}</ref> <ref>[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref>==
==Platelet Inhibitors and PCI==
*[[Aspirin]] is one of the oldest [[platelet inhibitors]] and has been repeatedly shown to improve outcomes in [[CAD]] patients.
*Thienopyridines (like [[clopidogrel]], [[prasugrel]], [[ticagrelor]]) are becoming increasingly important in [[PCI]] patients due to their benefit in reducing [[stent thrombosis]].
*Along with [[aspirin]], [[thienopyridines]] (i.e. either [[prasugrel]] or [[clopidogrel]]) form the '''dual antiplatelet therapy''' that are now routinely recommended before or at the time of [[PCI]].
*An important advance in the treatment of patients with [[UA]]/[[NSTEMI]] who are undergoing [[PCI]] was the introduction of platelet GP IIb/IIIa receptor inhibitors(like [[abciximab]], [[tirofiban]], [[eptifibatide]]) in the 1990s. All three [[GP IIb/IIIa inhibitors]] have been shown to reduce the incidence of [[ischemic]] complications in patients with [[UA]]/[[NSTEMI]].
*[[Abciximab]] is not recommended if [[PCI]] is not planned.
 
===Clinical trial data:===
Multiple randomized trials have previously shown good outcomes with the use of [[GP IIb/IIIa inhibitors]] in [[UA]]/[[NSTEMI]] patients but some recent trials ave also shown that these results may be confined to high risk groups and those with [[troponin]] elevations.
*'''EARLY ACS trial'''<ref name="pmid19332455">{{cite journal |author=Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK |title=Early versus delayed, provisional eptifibatide in acute coronary syndromes |journal=[[The New England Journal of Medicine]] |volume=360 |issue=21 |pages=2176–90 |year=2009 |month=May |pmid=19332455 |doi=10.1056/NEJMoa0901316 |url=http://dx.doi.org/10.1056/NEJMoa0901316 |accessdate=2011-04-13}}</ref> revealed that in patients who had [[acute coronary syndromes]] without ST-segment elevation, the use of [[eptifibatide]] 12 hours or more before [[angiography]] was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion.
*'''ISAR-REACT 2 trial'''<ref name="pmid16533938">{{cite journal |author=Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A |title=Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=295 |issue=13 |pages=1531–8 |year=2006 |month=April |pmid=16533938 |doi=10.1001/jama.295.13.joc60034 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=16533938 |accessdate=2011-04-13}}</ref> studied [[abciximab]] in [[NSTEMI]] patients. This was a multicenter, randomized, double-blind, placebo-controlled study enrolling 2022 patients with [[NSTEMI]] undergoing [[PCI]]. Results showed that [[abciximab]] reduces the risk of adverse events in patients with [[NSTEMI]] undergoing PCI after pretreatment with 600 mg of [[clopidogrel]]. The benefits provided by abciximab appear to be confined to patients presenting with an elevated [[troponin]] level. The benefit of [[GP IIb/IIIa inhibition]] appears greater when used in high-risk patients and in those with [[ST segment]] changes. The benefit was also seen in high risk patients with or without [[revascularization]].
*In the '''ACUITY trial'''<ref name="pmid17299194">{{cite journal |author=Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD |title=Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=297 |issue=6 |pages=591–602 |year=2007 |month=February |pmid=17299194 |doi=10.1001/jama.297.6.591 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=17299194 |accessdate=2011-04-13}}</ref> superiority of early [[GP IIb/IIIa inhibitor]] therapy also was not found, but investigators could not exclude as much as a 29% benefit with GP IIb/IIIa therapy nor show non inferiority of delayed administration. In addition, drug exposure before [[angiography]] was much shorter (4 hours), which might substantially diminish the opportunity for differential efficacy. Despite a lack of clarity from the overall and subgroup results, an argument can be made against the routine upstream use of GP IIb/IIIa therapy in all [[NSTEMI]] patients intended for an invasive strategy. In particular, those with a normal baseline [[troponin]] level and those over the age of 75 years, in whom there was no evidence for benefit but who showed an increased risk of bleeding, might be excluded. On the other hand, high risk patients, [[diabetic]] patients and those with [[troponin]] elevation have been shown to have positive trends which go along with the results of previous trials. Although, this puts forward a debate to the routine early use of [[GP IIb/IIIa inhibitors]] in [[UA]]/[[NSTEMI]] patients, the current guidelines favor the use of [[GP IIb/IIIa inhibitors]] in patients undergoing [[PCI]].
 
Also refer to the section on [[PCI]].
 
===ACC/AHA Guidelines for the Timing of Angiography and Antiplatelet Therapy in UA/NSTEMI(DO NOT EDIT)<ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=[[Journal of the American College of Cardiology]] |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi=10.1016/j.jacc.2007.02.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00511-6 |accessdate=2011-04-13}}</ref><ref>[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref>===
 
{{cquote|
{{cquote|
===Class I===
===Class I===
1. Patients with definite or likely UA/NSTEMI selected for an invasive approach should receive dual-antiplatelet therapy ''(Level of Evidence: A)''. [[Aspirin]] should be initiated on presentation ''(Level of Evidence: A)'', [[clopidogrel]] (before or at the time of PCI) ''(Level of Evidence: A)'' or [[prasugrel]] (at the time of PCI) ''(Level of Evidence: B)'' is recommended as a second antiplatelet agent.
'''1.''' Patients with definite or likely [[UA]]/[[NSTEMI]] selected for an invasive approach should receive [[dual antiplatelet therapy]] ''(Level of Evidence: A)''. [[Aspirin]] should be initiated on presentation ''(Level of Evidence: A)'', [[clopidogrel]] (before or at the time of PCI) ''(Level of Evidence: A)'' or [[prasugrel]] (at the time of PCI) ''(Level of Evidence: B)'' is recommended as a second [[antiplatelet]] agent.


===Class IIa===
===Class IIa===
1. It is reasonable for initially stabilized high-risk patients with [[UA]]/[[NSTEMI]] (GRACE i.e. Global Registry of Acute Coronary Events, risk score greater than 140) to undergo an early invasive strategy within 12 to 24 hours of admission. For patients not at high risk, an early invasive approach is also reasonable. ''(Level of Evidence: B)''}}
'''1.''' It is reasonable for initially stabilized high-risk patients with [[UA]]/[[NSTEMI]] ([[GRACE risk score]] greater than 140) to undergo an early invasive strategy within 12 to 24 hours of admission. For patients not at high risk, an early invasive approach is also reasonable. ''(Level of Evidence: B)''}}
 




Line 76: Line 87:


==Sources==
==Sources==
*The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, ''et al'' |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=JACC |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi:10.1016/j.jacc.2007.02.013 |url=}}</ref>
*The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=[[Journal of the American College of Cardiology]] |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi=10.1016/j.jacc.2007.02.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00511-6 |accessdate=2011-04-13}}</ref>
*The ACC/AHA 2009 Guidelines for STEMI and PCI: Focused updates<ref>[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref>
*The ACC/AHA 2009 Guidelines for STEMI and PCI: Focused updates<ref>[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref>


==References==
==References==
{{reflist|2}}
{{reflist}}


{{SIB}}
{{SIB}}

Revision as of 18:22, 13 April 2011

WikiDoc Resources for Unstable angina non ST elevation myocardial infarction recommendations for PCI

Articles

Most recent articles on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Most cited articles on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Review articles on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Articles on Unstable angina non ST elevation myocardial infarction recommendations for PCI in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Images of Unstable angina non ST elevation myocardial infarction recommendations for PCI

Photos of Unstable angina non ST elevation myocardial infarction recommendations for PCI

Podcasts & MP3s on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Videos on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Evidence Based Medicine

Cochrane Collaboration on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Bandolier on Unstable angina non ST elevation myocardial infarction recommendations for PCI

TRIP on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Clinical Trials

Ongoing Trials on Unstable angina non ST elevation myocardial infarction recommendations for PCI at Clinical Trials.gov

Trial results on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Clinical Trials on Unstable angina non ST elevation myocardial infarction recommendations for PCI at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Unstable angina non ST elevation myocardial infarction recommendations for PCI

NICE Guidance on Unstable angina non ST elevation myocardial infarction recommendations for PCI

NHS PRODIGY Guidance

FDA on Unstable angina non ST elevation myocardial infarction recommendations for PCI

CDC on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Books

Books on Unstable angina non ST elevation myocardial infarction recommendations for PCI

News

Unstable angina non ST elevation myocardial infarction recommendations for PCI in the news

Be alerted to news on Unstable angina non ST elevation myocardial infarction recommendations for PCI

News trends on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Commentary

Blogs on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Definitions

Definitions of Unstable angina non ST elevation myocardial infarction recommendations for PCI

Patient Resources / Community

Patient resources on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Discussion groups on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Patient Handouts on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Directions to Hospitals Treating Unstable angina non ST elevation myocardial infarction recommendations for PCI

Risk calculators and risk factors for Unstable angina non ST elevation myocardial infarction recommendations for PCI

Healthcare Provider Resources

Symptoms of Unstable angina non ST elevation myocardial infarction recommendations for PCI

Causes & Risk Factors for Unstable angina non ST elevation myocardial infarction recommendations for PCI

Diagnostic studies for Unstable angina non ST elevation myocardial infarction recommendations for PCI

Treatment of Unstable angina non ST elevation myocardial infarction recommendations for PCI

Continuing Medical Education (CME)

CME Programs on Unstable angina non ST elevation myocardial infarction recommendations for PCI

International

Unstable angina non ST elevation myocardial infarction recommendations for PCI en Espanol

Unstable angina non ST elevation myocardial infarction recommendations for PCI en Francais

Business

Unstable angina non ST elevation myocardial infarction recommendations for PCI in the Marketplace

Patents on Unstable angina non ST elevation myocardial infarction recommendations for PCI

Experimental / Informatics

List of terms related to Unstable angina non ST elevation myocardial infarction recommendations for PCI

Cardiology Network

Discuss Unstable angina non ST elevation myocardial infarction recommendations for PCI further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Associate Editor-In-Chief: Smita Kohli, M.D.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview of Recommendations for Percutaneous coronary intervention (PCI) in Unstable angina/NSTEMI

ACC / AHA Guidelines-Recommendations for PCI in patients with UA/NSTEMI (DO NOT EDIT) [1]

“

Class I

1. An early invasive PCI strategy is indicated for patients with UA / NSTEMI who have no serious comorbidity and who have coronary lesions amenable to PCI and any of the high risk features.

2. Percutaneous coronary intervention (or CABG) is recommended for UA / NSTEMI patients with 1 or 2 vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high risk criteria on non invasive testing. (Level of Evidence: B)

3. Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with multi vessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)

4. An intravenous platelet GP IIb/IIIa inhibitor is generally recommended in UA/NSTEMI patients undergoing PCI. (Level of Evidence: A)

Class IIa

1. Percutaneous coronary intervention is reasonable for focal saphenous vein graft (SVG) lesions or multiple stenosis in UA / NSTEMI patients who are undergoing medical therapy and who are poor candidates for reoperative surgery. (Level of Evidence: C)

2. Percutaneous coronary intervention (or CABG) is reasonable for UA / NSTEMI patients with 1 or 2 vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)

3. Percutaneous coronary intervention (or CABG) can be beneficial compared with medical therapy for UA / NSTEMI patients with 1 vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)

4. Use of PCI is reasonable in patients with UA / NSTEMI with significant left main CAD (>50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG or who require emergent intervention at angiography for hemodynamic instability. (Level of Evidence: B)

Class IIb

1. In the absence of high-risk features associated with UA / NSTEMI, PCI may be considered in patients with single-vessel or multi vessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. (Level of Evidence: B)

2. Percutaneous coronary intervention may be considered for UA / NSTEMI patients who are undergoing medical therapy who have 2 or 3 vessel disease, significant proximal left anterior descending CAD, and treated diabetes or abnormal LV function, with anatomy suitable for catheter based therapy. (Level of Evidence: B)

Class III

1. Percutaneous coronary intervention (or CABG) is not recommended for patients with 1 or 2 vessel CAD without significant proximal left anterior descending CAD with no current symptoms or symptoms that are unlikely to be due to myocardial ischemia and who have no ischemia on noninvasive testing. (Level of Evidence: C)

2. In the absence of high risk features associated with UA / NSTEMI, PCI is not recommended for patients with UA / NSTEMI who have single vessel or multi vessel CAD and no trial of medical therapy, or who have one or more of the following:

a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. (Level of Evidence: C)
c. A high risk of procedure related morbidity or mortality. (Level of Evidence: C)
d. Insignificant disease (<50% coronary stenosis). (Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of Evidence: B)

3. A PCI strategy in stable patients with persistently occluded infarct related coronary arteries after NSTEMI is not indicated. (Level of Evidence: B)

”


Platelet Inhibitors and PCI

Clinical trial data:

Multiple randomized trials have previously shown good outcomes with the use of GP IIb/IIIa inhibitors in UA/NSTEMI patients but some recent trials ave also shown that these results may be confined to high risk groups and those with troponin elevations.

  • EARLY ACS trial[2] revealed that in patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion.
  • ISAR-REACT 2 trial[3] studied abciximab in NSTEMI patients. This was a multicenter, randomized, double-blind, placebo-controlled study enrolling 2022 patients with NSTEMI undergoing PCI. Results showed that abciximab reduces the risk of adverse events in patients with NSTEMI undergoing PCI after pretreatment with 600 mg of clopidogrel. The benefits provided by abciximab appear to be confined to patients presenting with an elevated troponin level. The benefit of GP IIb/IIIa inhibition appears greater when used in high-risk patients and in those with ST segment changes. The benefit was also seen in high risk patients with or without revascularization.
  • In the ACUITY trial[4] superiority of early GP IIb/IIIa inhibitor therapy also was not found, but investigators could not exclude as much as a 29% benefit with GP IIb/IIIa therapy nor show non inferiority of delayed administration. In addition, drug exposure before angiography was much shorter (4 hours), which might substantially diminish the opportunity for differential efficacy. Despite a lack of clarity from the overall and subgroup results, an argument can be made against the routine upstream use of GP IIb/IIIa therapy in all NSTEMI patients intended for an invasive strategy. In particular, those with a normal baseline troponin level and those over the age of 75 years, in whom there was no evidence for benefit but who showed an increased risk of bleeding, might be excluded. On the other hand, high risk patients, diabetic patients and those with troponin elevation have been shown to have positive trends which go along with the results of previous trials. Although, this puts forward a debate to the routine early use of GP IIb/IIIa inhibitors in UA/NSTEMI patients, the current guidelines favor the use of GP IIb/IIIa inhibitors in patients undergoing PCI.

Also refer to the section on PCI.

ACC/AHA Guidelines for the Timing of Angiography and Antiplatelet Therapy in UA/NSTEMI(DO NOT EDIT)[1][5]

“

Class I

1. Patients with definite or likely UA/NSTEMI selected for an invasive approach should receive dual antiplatelet therapy (Level of Evidence: A). Aspirin should be initiated on presentation (Level of Evidence: A), clopidogrel (before or at the time of PCI) (Level of Evidence: A) or prasugrel (at the time of PCI) (Level of Evidence: B) is recommended as a second antiplatelet agent.

Class IIa

1. It is reasonable for initially stabilized high-risk patients with UA/NSTEMI (GRACE risk score greater than 140) to undergo an early invasive strategy within 12 to 24 hours of admission. For patients not at high risk, an early invasive approach is also reasonable. (Level of Evidence: B)

”


See Also

Sources

  • The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [1]
  • The ACC/AHA 2009 Guidelines for STEMI and PCI: Focused updates[6]

References

  1. ↑ 1.0 1.1 1.2 Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". Journal of the American College of Cardiology. 50 (7): e1–e157. doi:10.1016/j.jacc.2007.02.013. PMID 17692738. Retrieved 2011-04-13. Unknown parameter |month= ignored (help)
  2. ↑ Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK (2009). "Early versus delayed, provisional eptifibatide in acute coronary syndromes". The New England Journal of Medicine. 360 (21): 2176–90. doi:10.1056/NEJMoa0901316. PMID 19332455. Retrieved 2011-04-13. Unknown parameter |month= ignored (help)
  3. ↑ Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A (2006). "Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial". JAMA : the Journal of the American Medical Association. 295 (13): 1531–8. doi:10.1001/jama.295.13.joc60034. PMID 16533938. Retrieved 2011-04-13. Unknown parameter |month= ignored (help)
  4. ↑ Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD (2007). "Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial". JAMA : the Journal of the American Medical Association. 297 (6): 591–602. doi:10.1001/jama.297.6.591. PMID 17299194. Retrieved 2011-04-13. Unknown parameter |month= ignored (help)
  5. ↑ [1]
  6. ↑ [2]

Template:SIB

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Unstable_angina_non_ST_elevation_myocardial_infarction_recommendations_for_PCI&oldid=573502"